Adherence and persistence to second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

被引：0
|
作者：
Trivedi, Digisha
Amin, Shahla
Zhu, Ling
Joo, Sam
Kawabata, Hugh
Darkow, Theodore
Hebden, Tony
机构：
[1] Bristol Myers Squibb, Hlth Serv, Plainsboro, NJ USA
[2] Bristol Myers Squibb Co, Global Hlth Econ & Outcomes Res, Pennington, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17009
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib
    Breccia, Massimo
    Palandri, Francesca
    Iori, Anna Paola
    Colaci, Elisabetta
    Latagliata, Roberto
    Castagnetti, Fausto
    Torelli, Giovanni Fernando
    Usai, Sara
    Valle, Veronica
    Martinelli, Giovanni
    Rosti, Gianantonio
    Foa, Robin
    Baccarani, Michele
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2010, 34 (02) : 143 - 147
  • [22] Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML)
    Santos, Fabio P. S.
    Kantarjian, Hagop
    Fava, Carmen
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Komblau, Steven
    Ravandi, Farhad
    Wierda, William
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1104 - 1104
  • [23] Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia
    Shin-ichiro Fujiwara
    Yuya Shirato
    Takashi Ikeda
    Shin-ichiro Kawaguchi
    Yumiko Toda
    Shoko Ito
    Shin-ichi Ochi
    Takashi Nagayama
    Kiyomi Mashima
    Kento Umino
    Daisuke Minakata
    Hirofumi Nakano
    Kaoru Morita
    Ryoko Yamasaki
    Yasufumi Kawasaki
    Miyuki Sugimoto
    Masahiro Ashizawa
    Chihiro Yamamoto
    Kaoru Hatano
    Kazuya Sato
    Iekuni Oh
    Ken Ohmine
    Kazuo Muroi
    Yoshinobu Kanda
    International Journal of Hematology, 2018, 107 : 712 - 715
  • [24] Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed
    Ibrahim, Amr R.
    Clark, Richard E.
    Holyoake, Tessa L.
    Byrne, Jenny
    Shepherd, Pat
    Apperley, Jane F.
    Milojkovic, Dragana
    Szydlo, Richard
    Goldman, John
    Marin, David
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (12): : 1779 - 1782
  • [25] Second-Generation Tyrosine Kinase Inhibitors Combined With Stem Cell Transplantation in Patients With Imatinib-Refractory Chronic Myeloid Leukemia
    Zhao, Yanmin
    Luo, Yi
    Shi, Jimin
    Cai, Zhen
    Huang, He
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2014, 347 (06): : 439 - 445
  • [26] Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Jung, Y. S.
    Kim, M.
    Lee, J. H.
    Kim, D. W.
    Park, H. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (02) : 456 - 458
  • [27] Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
    Dusetzina, Stacie B.
    Winn, Aaron N.
    Abel, Gregory A.
    Huskamp, Haiden A.
    Keating, Nancy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04) : 306 - 311
  • [28] First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
    Oehler, Vivian G.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 228 - 236
  • [29] Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia
    Bostan, Hayri
    Toptas, Tayfur
    Tanrikulu, Funda Pepedil
    Kut, Kevser
    Arikan, Fatma
    Yilmaz, Fergun
    Atagunduz, Isik
    Firatli-Tuglular, Tulin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12): : 836 - 842
  • [30] Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Breccia, M.
    Alimena, G.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (04) : 391 - 401
12345